Relay Therapeutics Stock Alpha and Beta Analysis
| RLAY Stock | USD 4.70 0.10 2.08% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Relay Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Relay Therapeutics over a specified time horizon. Remember, high Relay Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Relay Therapeutics' market risk premium analysis include:
Beta 3.79 | Alpha (0.84) | Risk 7.52 | Sharpe Ratio (0.04) | Expected Return (0.27) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Relay |
Relay Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Relay Therapeutics market risk premium is the additional return an investor will receive from holding Relay Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Relay Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Relay Therapeutics' performance over market.| α | -0.84 | β | 3.79 |
Relay Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Relay Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Relay Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Relay Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Relay Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Relay Therapeutics shares will generate the highest return on investment. By understating and applying Relay Therapeutics stock market price indicators, traders can identify Relay Therapeutics position entry and exit signals to maximize returns.
Relay Therapeutics Return and Market Media
The median price of Relay Therapeutics for the period between Mon, Sep 2, 2024 and Sun, Dec 1, 2024 is 6.47 with a coefficient of variation of 15.7. The daily time series for the period is distributed with a sample standard deviation of 1.01, arithmetic mean of 6.43, and mean deviation of 0.75. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market | 09/10/2024 |
2 | Disposition of 1657 shares by Peter Rahmer of Relay Therapeutics at 11.16 subject to Rule 16b-3 | 09/23/2024 |
3 | Disposition of 295 shares by Thomas Catinazzo of Relay Therapeutics at 7.51 subject to Rule 16b-3 | 10/01/2024 |
4 | Biotech layoff tracker 13 biotechs cut over 1,400 jobs | 10/02/2024 |
5 | Short Interest in Relay Therapeutics, Inc. Grows By 24.7 | 10/15/2024 |
6 | Institutional owners may consider drastic measures as Relay Therapeutics, Inc.s recent US67m drop adds to long-term losses | 10/28/2024 |
7 | Disposition of 2300 shares by Thomas Catinazzo of Relay Therapeutics at 5.95 subject to Rule 16b-3 | 10/29/2024 |
8 | Relay Therapeutics, Inc. CFO Thomas Catinazzo Sells 6,802 Shares | 10/31/2024 |
9 | Relay Therapeutics Issues Earnings Results | 11/07/2024 |
10 | Cornercap Investment Counsel Inc. Trims Holdings in Relay Therapeutics, Inc. | 11/19/2024 |
11 | Down -27.93 percent in 4 Weeks, Heres Why Relay Therapeutics Looks Ripe for a Turnaround | 11/20/2024 |
12 | Disposition of 19864 shares by Peter Rahmer of Relay Therapeutics at 6.47 subject to Rule 16b-3 | 11/25/2024 |
13 | Braidwell LP Buys 492,628 Shares of Relay Therapeutics, Inc. | 11/29/2024 |
About Relay Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Relay or other stocks. Alpha measures the amount that position in Relay Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 (projected) | Net Debt To EBITDA | 3.07 | 0.24 | 0.23 | Intangibles To Total Assets | 0.002091 | 0.002725 | 0.001893 |
Relay Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Relay Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Relay Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Relay Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Relay Therapeutics. Please utilize our Beneish M Score to check the likelihood of Relay Therapeutics' management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Relay Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.